UPSTREAM BIO, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
UPSTREAM BIO, INC. (UPB) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 9.62 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-11
- UPSTREAM BIO, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 9.34M shares, a 17.85% increase year-over-year.
- UPSTREAM BIO, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 7.93M shares, a 71.61% decline year-over-year.
- UPSTREAM BIO, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2024-03-31 was 27.93M shares.
- UPSTREAM BIO, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 6.49M shares, a 77.01% decline from fiscal 2023.
- UPSTREAM BIO, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 28.23M shares.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | 9.62M shares 10-Q · filed 2026-08-11 | |||
| 2026-03-31 | 9.34M shares 10-Q · filed 2026-05-13 | |||
| 2025-09-30 | 8.14M shares 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | 8.25M shares 10-Q · filed 2026-08-11 | |||
| 2025-03-31 | 7.93M shares 10-Q · filed 2026-05-13 | |||
| 2024-12-31 | 6.49M shares 10-K · filed 2025-03-12 | |||
| 2024-09-30 | 39.56M shares 10-Q · filed 2025-11-05 | |||
| 2024-06-30 | 39.55M shares 10-Q · filed 2025-08-06 | |||
| 2024-03-31 | 27.93M shares 10-Q · filed 2025-05-06 | |||
| 2023-12-31 | 28.23M shares 10-K · filed 2025-03-12 | |||
| 2023-09-30 | 28.25M shares 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |